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Abstract 
Background: Insulin-induced microvascular recruitment is important for optimal muscle glucose uptake. 
5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR, an activator of AMP-activated protein kinase), can also 
induce microvascular recruitment, at doses that do not acutely activate glucose transport in rat muscle. Whether low 
doses of AICAR can augment physiologic insulin action is unknown. In the present study we used the euglycemic 
hyperinsulinemic clamp to assess whether insulin action is augmented by low dose AICAR.
Methods: Anesthetized rats were studied during saline infusion or euglycemic insulin (3 mU/kg/min) clamp for 2 h in 
the absence or presence of AICAR for the last hour (5 mg bolus followed by 3.75 mg/kg/min). Muscle glucose uptake 
(R’g) was determined radioisotopically with 14C-2-deoxyglucose and muscle microvascular perfusion by contrast-
enhanced ultrasound with microbubbles.
Results: AICAR did not affect blood glucose, or lower leg R’g, although it significantly (p < 0.05) increased blood lac-
tate levels and augmented muscle microvascular blood volume via a nitric oxide synthase dependent pathway. Insu-
lin increased femoral blood flow, whole body glucose infusion rate (GIR), R’g, hindleg glucose uptake, and microvascu-
lar blood volume. Addition of AICAR during insulin infusion increased lactate production, further increased R’g in Type 
IIA (fast twitch oxidative) and IIB (fast twitch glycolytic) fiber containing muscles, and hindleg glucose uptake, but 
decreased R’g in the Type I (slow twitch oxidative) fiber muscle. AICAR also decreased GIR due to inhibition of insulin-
mediated suppression of hepatic glucose output. AICAR augmented insulin-mediated microvascular perfusion.
Conclusions: AICAR, at levels that have no direct effect on muscle glucose uptake, augments insulin-mediated 
microvascular blood flow and glucose uptake in white fiber type muscles. Agents targeted to endothelial AMPK 
activation are promising insulin sensitizers, however, the decrease in GIR and the propensity to increase blood lactate 
cautions against AICAR as an acute insulin sensitizer.
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Background
Insulin stimulates skeletal muscle glucose uptake in vivo 
indirectly by regulating microvascular blood flow [1–4] 
and directly via insulin receptors on the myocytes result-
ing in increased GLUT4 translocation to the sarcolemma 
[5, 6]. The insulin-mediated vascular responses facilitate 
insulin and glucose delivery to the myocytes and have 
been shown to occur in both humans [7–10] and experi-
mental animals [1, 3, 11]. The recruitment of microvascu-
lar blood flow by insulin is impaired in insulin-resistant 
rats [12–14] and humans [7, 8]. Loss of insulin-mediated 
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microvascular recruitment in muscle can alone result in 
whole body insulin resistance equivalent to that caused 
by obesity [11, 12], emphasizing the physiological impor-
tance of this process [15].
Insulin’s hemodynamic actions in  vivo appear to be 
mediated, at least in part, by nitric oxide (NO) depend-
ent processes [16, 17], and local nitric oxide synthase 
(NOS) inhibition impairs insulin-mediated microvascu-
lar recruitment and decreases insulin-mediated skeletal 
muscle glucose uptake [18]. However, simply delivering 
NO to the muscle vasculature does not lead to micro-
vascular recruitment or enhance insulin-mediated mus-
cle glucose uptake [19, 20] but appears to require insulin 
action at specific vascular sites [15, 20, 21].
Insulin has been shown to activate the PI3K/Akt 
pathway leading to phosphorylation and activation of 
endothelial nitric oxide synthase (eNOS) and NO pro-
duction [22, 23]. Inhibition of PI3K by wortmannin in 
rats in vivo also leads to loss of insulin-mediated micro-
vascular recruitment in muscle suggesting this pathway 
is important [24]. The phosphorylation and activation of 
eNOS can also occur by other kinase pathways and we 
have reported that activation of AMP-activated protein 
kinase (AMPK) by 5-aminoimidazole-4-carboxamide-
1-β-d-ribofuranoside (AICAR) increases NO synthe-
sis and muscle microvascular perfusion [25]. AICAR, at 
high doses acutely activates glucose transport in resting 
rat muscle in  vitro [26, 27] and in  vivo [28], however it 
is not known if lower doses which do not have a direct 
metabolic action can sensitize physiologic insulin action. 
There have been few studies examining the effect of 
AMPK activation combined with insulin. Further, there 
have been no studies examining whether AMPK activa-
tion by AICAR improves the ability of insulin to increase 
microvascular perfusion in skeletal muscle. Thus, in 
the present study we have examined the acute effect of 
AICAR on muscle glucose uptake in vivo during a physi-
ologic insulin infusion. The dose of AICAR used was 
sufficient to cause microvascular recruitment but not 
stimulate muscle glucose uptake alone [25].
Methods
Animal care
All procedures adopted and experiments undertaken 
were approved by the University of Tasmania Animal 
Ethics Committee and performed in accordance with 
the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes—2004, 7th Edition. 
Male Hooded Wistar rats weighing 243 ± 1 g at the time 
of the experiments were obtained from the University 
of Tasmania Animal House (Hobart, Australia). Ani-
mals were raised on a commercial diet (Pivot, Launces-
ton, Australia) containing 21.4% protein, 4.6% lipid, 68% 
carbohydrate and 6% crude fiber with added vitamins 
and minerals together with water ad  libitum and were 
housed at 21 ± 1°C on a 12:12 h light:dark cycle.
Surgery
Complete details are as described previously [1]. Briefly, 
rats were anesthetized and cannulas surgically implanted 
into a carotid artery for arterial sampling and measure-
ment of blood pressure, and into both jugular veins for 
continuous administration of anesthetic and other intra-
venous infusions. Animals were allowed to spontane-
ously breathe room air through a tracheostomy tube. 
Animals were maintained at 37°C under anesthesia for 
the duration of the experiment using a continual infusion 
of sodium pentobarbital (0.6 mg/kg/min) via the left jug-
ular cannula. Once the surgery was completed, a period 
of equilibration of approximately 60 min was allowed so 
that cardiovascular parameters could become stable and 
constant.
Experimental protocols
All animals underwent one of the three following proto-
cols in Figure 1.
Procotol A: metabolic and hemodynamic actions of AICAR
Rats were randomly assigned into four experimental 
groups: (1) saline, n =  33 (2) AICAR (3.75  mg/min/kg, 
Sigma-Aldrich., St. Louis, MO, USA), n  =  16 (3) insu-
lin (3  mU/min/kg, Human R Eli Lilly, Indianapolis, IN, 
USA), n = 39 or (4) insulin + AICAR (3 mU/min/kg and 
3.75 mg/min/kg respectively), n = 18.
AICAR administration was initiated by an intravenous 
bolus injection (20  mg/kg) at t =  60  min followed by a 
constant infusion (3.75 mg/min/kg, via the jugular vein) 
for the remainder of the experiment. Hyperinsulinemic 
euglycemic clamps (3  mU/min/kg) were performed in 
the insulin and insulin + AICAR groups to assess insulin 
sensitivity. Insulin infusions commenced at t = 0 min and 
continued until the end of the experiment. In the experi-
ments where rats received insulin, basal blood glucose 
concentration was maintained (euglycemia) by co-infu-
sion of variable rates of glucose (30% w/v solution) over 
the course of the experiment.
Epigastric vessels were ligated, and an ultrasonic flow 
probe (Transonic Systems, VB series 0.5 mm) was posi-
tioned around the femoral artery of the right leg just 
distal to the rectus abdominis muscle. Data for femoral 
artery blood flow (FBF), heart rate (HR), and blood pres-
sure (BP) were sampled using WINDAQ data acquisition 
software (DATAQ Instruments).
Blood and plasma samples were collected from the 
carotid artery (A) and femoral vein (V) for deter-
mination of blood and plasma glucose, and blood 
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lactate concentration at the end of the experiment. 
Hindleg glucose uptake was calculated from the 
arterio-venous difference (A–V) multiplied by the 
FBF (the Fick Principle) and expressed as µmol/min. 
The calf muscles (gastrocnemius, soleus and plan-
taris) were removed from the right leg and freeze 
clamped in  situ at the conclusion of the experi-
ment and stored at −80°C for later determination of 
AICAR and 5-Aminoimidazole-4-carboxamide-1-β-
d-ribofuranosyl 5′-monophosphate (ZMP) content. 
Both of these metabolites were measured because 
AICAR is taken up by cells and converted to its active 
form ZMP.
Muscle glucose uptake was also assessed using iso-
topic tracers. A intravenous bolus dose (50 µCi, 0.2 ml) 
of 2-deoxy-d-[1-14C]glucose (2-DG), specific activity 
1.85-2.29  GBq/mmol; Amersham Life Science, Castle 
Hill, NSW, Australia) was given 45  min before the end 
of the experiment. The plasma specific activity of 2-DG 
was determined from plasma samples (25µL) collected 
at 5, 10, 15, 30 and 45  min after administration of the 
2-DG bolus. At the conclusion of the experiment, indi-
vidual muscles [soleus, plantaris (Plant), gastrocnemius 
red (GR), gastrocnemius white (GW), extensor digito-
rum longus (EDL) and tibialis (Tib)] from the lower left 
hindlimb were rapidly removed, frozen in liquid nitrogen 
and stored at −80°C until assayed for 2-DG radioactivity 
and the determination of muscle specific glucose uptake 
as described previously [18].
Effect of fasting on AICAR‑mediated metabolic actions
A sub-set of insulin  +  AICAR experiments were per-
formed using a modified version of protocol A, to assess 
effect of fasting on AICAR-mediated metabolic actions. 
These experiments were carried out in order to deter-
mine the effect of AICAR on insulin-mediated metabolic 
responses with different degrees of liver glycogen content 
(i.e. prolonged fasting depletes liver glycogen). All rats 
underwent insulin + AICAR (3 mU/min/kg and 3.75 mg/
min/kg, respectively) infusion. Rats were randomly 
assigned into two experimental groups: (1) overnight fast 
(which represents abstaining from food for 16 h), n = 12 
or (2) prolonged fast (which represents abstaining from 
food for 40 h), n = 16. Whole body GIR and muscle spe-
cific glucose uptake (by isotopic tracer) was performed as 
described above.
Protocol B: muscle microvascular actions of AICAR
The effect of AICAR on microvascular perfusion in skel-
etal muscle was assessed. These measures could not be 
conducted in Protocol A because microbubbles interfere 
with the Doppler signal from the Transonic flow probe 
used to measure FBF.
Rats were randomly assigned into four experimental 
groups: (1) saline, n  =  6 (2) AICAR (3.75  mg/min/kg, 
Sigma-Aldrich., St. Louis, MO, USA), n  =  6 (3) insu-
lin (3  mU/min/kg, Human R Eli Lilly, Indianapolis, IN, 
USA), n = 6 or (4) insulin + AICAR (3 mU/min/kg and 
3.75 mg/min/kg respectively), n = 6.
AICAR, insulin or saline infusion was identical to the 
procedure described in protocol A. Muscle microvascular 
Figure 1 Animals were subject to a 2 h euglycemic clamp of 3 mU/
kg/min insulin or saline infusion with or without AICAR. Arterial blood 
samples (droplets) were taken for glucose and lactate analysis. A bolus 
injection (i.v.) of AICAR (20 mg/kg) is indicated by pointing hand and 
followed by AICAR infusion (3.75 mg/min/kg). Other bolus infusions 
are indicated by pointing hand. In protocol A, arterial and venous 
blood samples were taken (indicated as A–V) for plasma glucose 
determination as well as arterial insulin and AICAR determination. 
The gastrocnemius group of muscles was freeze clamped at 120 min 
for the determination of AICAR and ZMP content as well as R’g 
determination. In protocol B, microbubble infusion (40 µL/min) and 
periods where ultrasound measurement of MvV and MvP were made 
are shown by CEU. Muscle contraction (field stimulation, 2 Hz, 0.1 ms, 
30–50 V) is indicated by EX. In protocol C L-NAME (NOS inhibitor) was 
infused 15 min prior to and during AICAR infusion.
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perfusion was assessed by contrast-enhanced ultrasound 
(CEU) as described previously [2].
CEU imaging occurred at baseline (t =  0 min) and at 
the end of the experiment (t = 120 min) to assess micro-
vascular responses to saline, AICAR, insulin and Insu-
lin  +  AICAR. Contraction is a well-accepted stimulus 
for maximal microvascular recruitment. At the end of 
the experiment, an incision was made through the skin 
at the lateral side of the hip. Electrodes were attached 
to the muscle of the hindleg and the Achilles tendon. 
Twitch contraction was performed with 0.1 ms pulses of 
30–50  V. Microvascular responses to contraction were 
assessed by CEU at the time indicated (Figure 1b).
CEU imaging
The adductor magnus and semimembranosus muscles of 
the left hind limb were imaged in short axis with a lin-
ear array transducer (L7-4), secured in position for the 
duration of the experiment, connected to an ultrasound 
system (HDI-5000, Ultrasound, Phillips Ultrasound). 
The acoustic focus was set at the mid-muscle level and 
gain settings were optimised and held constant through-
out the experiment. Albumin microbubbles (Optison™, 
GE Healthcare) were diluted 1:5 with perfluoropropane 
gassed saline and infused via the jugular vein at 40  µL/
min for the duration of the data acquisition. The acoustic 
signal that is generated from the microbubbles exposed 
to ultrasound is proportional to the concentration of 
microbubbles within the volume of tissue being imaged. 
All microbubbles within the ultrasound beam are simul-
taneously imaged and destroyed in response to a single 
pulse of high-energy ultrasound. As the time between 
successive pulses is prolonged, the beam becomes pro-
gressively replenished with microbubbles (refer to Figure 
in [2]). The beam will eventually become fully replen-
ished with microbubbles, and further increases in the 
time between each ultrasound pulse will not affect the 
microbubble signal in tissue. Intermittent imaging was 
performed using pulsing intervals (PIs) ranging from 0.5 
to 15  s to allow incremental microvascular replenish-
ment with microbubbles between each pulse until the 
volume within the beam was completely refilled. Sev-
eral frames were obtained at each PI. Data was analysed 
using QLAB™ Software (Version 6.0, Phillips Ultrasound, 
Bothwell). The ultrasound intensity in decibels within 
the region of interest (semimembranous and adductor 
magnus) were converted to acoustic intensity and after 
background subtraction using 0.5  s ultrasound images 
(to eliminate signal from larger blood vessels and muscle 
per se), a pulsing interval (time) versus acoustic-intensity 
curve was plotted. This allowed calculation of microvas-
cular volume (MvV) as well as an index of microvascu-
lar perfusion (MvP) according to the equation y  =  A 
(1 − e−β(t−0.5)) where y is the acoustic intensity at a given 
pulsing interval, A = MvV, and Axβ = MvP [2, 29].
Protocol C: role of NOS on AICAR‑mediated microvascular 
actions
We have previously demonstrated that insulin [4], but 
not contraction [30], stimulate microvascular recruit-
ment in muscle via NOS-dependent pathway. We 
wanted to determine whether AICAR-mediated micro-
vascular recruitment was similar to insulin or contrac-
tion. The femoral artery, femoral vein and nerve were 
all carefully separated. In one leg (test leg), the epigas-
tric artery was cannulated for infusion of Nω-l-nitro-
arginine-methyl ester (l-NAME, Sigma-Aldrich, St. 
Louis, MO, USA) to achieve 10 μM, and in the contralat-
eral leg (control leg), the epigastric artery was ligated. 
Rats were randomly assigned into two groups as follows; 
(1) AICAR (3.75 mg/min/g), n = 9, or (2) AICAR + local 
L-NAME, n =  9 (Figure  1c). We have previously dem-
onstrated that this dose of l-NAME supresses insulin-
mediated microvascular recruitment while avoiding 
systemic effects on blood pressure and heart rate [18]. 
Microvascular responses were assessed by CEU at base-
line (t = 0 min) and after AICAR or AICAR + l-NAME 
infusion. Similar to Protocol B, all animals underwent a 
bout of acute contraction to assess maximal microvascu-
lar recruitment.
Analytical methods
Blood glucose, plasma glucose and blood lactate concen-
trations were determined using a glucose analyzer (Yel-
low Springs Instruments, Model 2300 Stat plus). Plasma 
insulin concentrations were determined by ELISA (Mer-
codia, Uppsala, Sweden) from arterial plasma samples 
taken at beginning and the conclusion of the experiment. 
AICAR and ZMP concentrations were determined from 
perchloric acid treated plasma or homogenized muscle 
samples, that were centrifuged for 10 min and the super-
natant analysed using reverse-phase HPLC as generally 
used to resolve nucleoside mixtures [25, 31].
Statistical analysis
All data are presented as mean ± SE. Repeated-measures 
two-way ANOVA was used to determine if there were 
differences between treatment groups over the time 
course of the experiment, or one-way ANOVA was used 
for single point measurements. When a significant dif-
ference (p  <  0.05) was found, pair wise comparisons by 
the Student–Newman–Keuls test was used to determine 
treatment differences. Comparisons between the treat-
ments for plasma AICAR values were determined by an 
unpaired t test. All tests were performed using SigmaS-
tat™ (Systat Software, Inc., San Jose, CA, USA).
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Results
Procotol A: metabolic and hemodynamic actions of AICAR
Effect of AICAR infusion on insulin and blood glucose levels
We first determined whether AICAR infusion alters insu-
lin levels achieved during clamps, to exclude the possibil-
ity that alterations in glucose handling result solely from 
altered plasma insulin concentration. Plasma insulin con-
centration was significantly elevated (twofold, p  <  0.05) 
following insulin clamps (saline, 204  ±  28  pM; insu-
lin, 410 ±  34  pM) but this was not affected by AICAR 
(AICAR, 234 ± 52 pM; insulin + AICAR, 425 ± 29 pM). 
Blood glucose concentration was also unaffected by 
AICAR infusion during insulin clamps, and was main-
tained at fasting levels with no differences between 
groups (saline, 3.49 ± 0.12 mM; insulin, 3.75 ± 0.12 mM; 
saline  +  AICAR, 3.41  ±  0.14  mM; insulin  +  AICAR, 
3.41  ±  0.10  mM). However, blood lactate concentra-
tion significantly increased twofold (p < 0.05) with insu-
lin (saline, 0.44  ±  0.04  mM; insulin, 0.87  ±  0.09  mM) 
and this was further enhanced with AICAR (AICAR, 
3.52  ±  0.27  mM; insulin  +  AICAR, 2.46  ±  0.15  mM; 
Figure 2).
Effect of insulin on AICAR metabolism
In contrast to the lack of effect of AICAR on insulin, 
the converse was not true. Insulin infusion moderately 
(22%, p < 0.05) lowered plasma AICAR content (AICAR, 
266 ±  12  mM; insulin +  AICAR, 208 ±  12  mM), pos-
sibly due to a stimulating effect of insulin on whole 
body AICAR clearance. This did not appear to be due 
to altered hindleg AICAR uptake (arterio-venous dif-
ference  ×  flow), which was not significantly different 
between insulin (76.3  ±  10.7  nmol/min, n  =  12) and 
saline (69.6  ±  5.5  nmol/min, n  =  10) treated animals. 
Similarly, the concentration of AICAR and its metabolite 
ZMP in individual lower leg muscles was not significantly 
altered by insulin (Table  1). Despite this, both AICAR 
and ZMP content in soleus was significantly increased 
compared to gastrocnemius red (GR) and gastrocne-
mius white (GW) muscle in the AICAR group, although 
these differences became non-significant in the insu-
lin + AICAR group.
Effect of AICAR on whole body and muscle glucose uptakes
AICAR reduced (p  <  0.001) the glucose infusion rate 
(GIR) required to maintain blood glucose during the 
insulin clamp (9.9 ± 0.3 to 6.7 ± 0.3 mg/min/kg during 
the last 60  min; Figure  3a). No exogenous glucose was 
required to maintain blood glucose during the AICAR 
infusion confirming that this dose of AICAR does not 
have a direct metabolic effect.
Insulin significantly stimulated hindleg glucose uptake 
(HLGU, fourfold, p  <  0.05) and this was augmented by 
AICAR (p  <  0.001, sevenfold; Figure  3b). There was no 
significant difference between the saline and AICAR 
groups on HLGU, indicating that AICAR alone had no 
effect on glucose uptake. Similarly insulin increased 
muscle glucose uptake (R’g) when assessed by isotopic 
glucose tracer, and AICAR further enhanced insulin-
mediated R’g (p < 0.001, threefold, Figure 3c).
The AICAR-mediated decrease in GIR in the pres-
ence of increased muscle glucose uptake suggested that 
AICAR stimulated glucose production from glyco-
gen stores in the liver. This was confirmed in a subset 
Figure 2 Changes in arterial blood lactate (∆BL) in response to 
saline (unfilled circle), insulin (filled circle), AICAR (unfilled square) 
and AICAR + insulin (filled square) treatments. Values are given as 
mean ± SE. Asterisk AICAR treated significantly different (p < 0.05) 
from corresponding untreated animals. Hash Insulin + AICAR treated 
significantly different (p < 0.05) from insulin treated animals. Cap sym-
bol Insulin treated significantly different (p < 0.05) from saline treated 
animals. (Protocol A); 2-way repeated-measures ANOVA.
Table 1 Muscle content of AICAR and ZMP
Muscle content of AICAR and ZMP from AICAR and insulin + AICAR treated 
animals determined at t = 120 min. Values are mean ± SE.
GW Gastrocnemius white, GR Gastrocnemius red.
* AICAR and ZMP values significantly different (p < 0.05) from soleus values.
AICAR (n = 7) Insulin + AICAR (n = 4)
AICAR ZMP AICAR ZMP
(mmol/g wet wt) (mmol/g wet wt)
Soleus 161 ± 9 325 ± 31 152 ± 22 237 ± 33
Plantaris 116 ± 11* 252 ± 29 116 ± 17 207 ± 43
GW 98 ± 16* 170 ± 27* 86 ± 12 145 ± 25
GR 86 ± 7* 174 ± 30* 110 ± 13 188 ± 23
Page 6 of 12Bradley et al. Cardiovasc Diabetol  (2015) 14:91 
of experiments (Figure  4) in which rats were fasted for 
40  h to deplete liver glycogen stores and then were 
treated with AICAR and insulin. GIR in these 40 h fasted 
AICAR  +  insulin rats was significantly greater than 
insulin alone (Figure 4) indicating that AICAR does not 
impair GIR in glycogen depleted rats.
Figure 5 shows in a sub-group of experiments, the R’g of 
individual muscles of the lower leg. Insulin alone signifi-
cantly stimulated R’g in all muscles of the lower leg. AICAR 
infusion alone had no significant effects on R’g in any of 
the lower leg muscles. However, AICAR had disparate 
effects on the R’g in muscles of the lower leg in the pres-
ence of insulin. In the soleus, which is predominately fiber 
type I (slow twitch oxidative) [32], and the GR, which has 
a mix of type I and IIA (fast twitch oxidative) fibers [32], 
there was no significant effect. In contrast, AICAR signifi-
cantly increased insulin-mediated R’g in the muscles with 
a mixture of type IIA and IIB (fast twitch glycolytic) fibers 
[32], plantaris, GW, EDL and tibialis (Figure 5). Since these 
latter muscles make up the bulk of the muscle in the lower 
leg the overall effect of AICAR was a significant increase in 
insulin-mediated glucose uptake (Figure 5).
Effect of AICAR on hemodynamic measurements
Basal mean arterial pressure in anesthetized rats was 
not affected by insulin or AICAR and remained constant 
throughout the experiment for all groups (Figure  6a). 
While insulin did not alter heart rate, AICAR infusion 
significantly (p  <  0.05) reduced heart rate after the first 
15  min of AICAR in both the presence and absence of 
insulin, and remained depressed until the conclusion of 
the experiment (Figure  6b). Despite the drop in heart 
rate, AICAR did not significantly alter the increase in 
femoral artery blood flow (FBF) in response to insulin 
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Figure 3 Glucose infusion rate (a; GIR), hindleg glucose uptake (b; HLGU) and calf muscle specific glucose uptake (c; R’g) during saline (white), insu-
lin (grey), AICAR (hatched) and AICAR + insulin (black) treatments. Data are mean ± SE, (Protocol A). *p < 0.05 insulin vs respective saline, #p < 0.05 
insulin vs AICAR + insulin.
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b
Figure 4 Effect of insulin (unfilled square) and insulin + AICAR (filled 
square) [16 h fasted animals] and insulin + AICAR (crossed square) 
[40 h fasted animals] treatment on glucose infusion rate (GIR, a) and 
hindleg 2-deoxyglucose uptake (R’g, b). Values were determined at 
the end of the experiment (Protocol A) and are mean ± SE. Asterisk 
AICAR treated significantly different (p < 0.05) from correspond-
ing untreated animals; hash 40 h fast treated significantly different 
(p < 0.05) from corresponding 16 h fasted group (Protocol A); one-
way ANOVA.
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infusion, which became significant by t =  75  min (Fig-
ure 6c). The FBF in the AICAR alone group was not sig-
nificantly different from the saline control.
Protocol B: muscle microvascular actions of AICAR
Although AICAR did not alter arterial flow, it did 
enhance insulin-mediated muscle microvascular vol-
ume (MvV; Figure  7c) compared with insulin alone 
(Figure  7a). Indeed, while insulin alone produced the 
expected increase in MvV, the insulin +  AICAR com-
bination produced similar MvV values comparable to 
that produced by contraction (Figure  7c), which pro-
duces maximal MvV in muscle. Insulin infusion had 
no effect on microvascular perfusion (MvP), although 
as expected MvP significantly increased during con-
traction (Figure  7b). Insulin  +  AICAR treatment sig-
nificantly increased MvP compared to basal which 
was further significantly increased with contraction 
(Figure 7d).
Figure  8 compares the increases in MvV over time 
between saline, AICAR, insulin and AICAR  +  insulin 
treatments. The ∆MvV in the AICAR  +  insulin group 
was significantly higher than that of insulin alone, indi-
cating that the effects of AICAR and insulin on microvas-
cular volume are additive.
Protocol C: Role of NOS on AICAR‑mediated microvascular 
actions
Microvascular volume recruitment by AICAR was also 
demonstrated to be NOS-dependent (Figure 9). AICAR 
increased MvV by 40% (Figure  9a) and this was com-
pletely abolished by local hindleg infusion of the NOS 
inhibitor L-NAME (Figure  9b). Contraction stimu-
lated MvV by 110% and this was unaffected by NOS 
inhibition.
Discussion
This study was undertaken to investigate the effects of 
the AMPK activator AICAR on insulin-mediated micro-
vascular perfusion and glucose uptake in skeletal mus-
cle. The main findings were (1) acute administration of 
AICAR in vivo, at a dose which does not stimulate glu-
cose uptake by itself, improves insulin-mediated glucose 
uptake; (2) AICAR induced increases in insulin-mediated 
muscle glucose uptake which were greater in the Type IIb 
fiber type muscles; (3) AICAR increases MvV in skeletal 
muscle by a NOS-dependent pathway; and (4) AICAR 
augments insulin-stimulated MvV in skeletal muscle.
The effects of insulin to increase total blood flow and 
MvP in skeletal muscle have been well established [21] 
and were also observed in the present study. We have 
previously reported [25] that AICAR, at the dose used 
in this study, acutely increases MvV and MvP which was 
also confirmed in the current study. Plasma concentra-
tions of AICAR reached approximately 0.24  mM and 
although these treatments alone were without effect on 
muscle glucose uptake, they were found to markedly sen-
sitize insulin action on muscle glucose uptake. Bergeron 
et  al. [26] demonstrated that the effects of AICAR on 
glucose transport activity are additive with insulin. The 
results from the present study differ from Bergeron as 
a lower dose of AICAR was used which was below the 
threshold to stimulate glucose uptake, despite insulin-
mediated glucose uptake being markedly augmented. It is 
possible that increased insulin mediated glucose uptake 
in the presence of low dose AICAR is due to increased 
availability of glucose and insulin to muscle through 
enhancement of nutritive blood flow. It has been shown 
that there is a strong correlation between nutritive blood 
flow and glucose uptake in the presence of insulin [21], 
and other agents that enhance microvascular perfusion 
Figure 5 Muscle specific glucose uptake (R’g) for soleus, plantaris (plant.), gastrocnemius red (GR), gastrocnemius white (GW), extensor digitorum 
longus (EDL) and tibialis (Tib.) muscles during saline (open), insulin (grey), AICAR (hatched) and AICAR + insulin (black) treatments. Percent (%) fiber 
type is indicated by pie charts; Type I (slow twitch oxidative, (black); Type IIA (fast twitch oxidative, grey); Type IIB (fast twitch glycolytic, white). Data 
are mean ± SE, (Protocol A). *p < 0.05 insulin vs respective saline, #p < 0.05 insulin vs AICAR + insulin.
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(e.g. methacholine) have been shown to enhance insulin-
mediated muscle glucose uptake [20]. This study demon-
strated that AICAR-mediated microvascular recruitment 
is NOS-dependent. This is important because we have 
a
b
c
Figure 6 Mean arterial pressure (a; MAP), change in heart rate 
(b; ∆HR) and change in femoral artery blood flow (c; FBF) during 
saline (unfilled circle), insulin (filled circle), AICAR (unfilled square) 
and AICAR + insulin (filled square) treatments. Values are given as 
mean ± SE (Protocol A). Asterisk AICAR treated significantly different 
(p < 0.05) from corresponding untreated animals. Hash AICAR + insu-
lin treated significantly different (p < 0.05) from corresponding 
untreated animals. Cap symbol Insulin treated significantly different 
(p < 0.05) from saline animals; 2-way repeated-measures ANOVA.
a b
c d
Figure 7 Microvascular volume (MvV) (a and c) and microvas-
cular perfusion (MvP) (b and d) for basal (white), insulin (grey), 
insulin + AICAR (black) and contraction (cross hatched). Values are 
mean ± SE (Protocol B). *p < 0.05 vs basal; #p < 0.05 contraction vs 
untreated.
Figure 8 Change in microvascular volume (∆MvV,) for saline (white), 
insulin (grey), AICAR (hatched) and AICAR + insulin (black) treatments. 
Data are mean ± SE, (Protocol B). *p < 0.05 insulin vs respective 
control, #p < 0.05 AICAR vs respective control.
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similarly shown insulin to recruit flow to the microcircu-
lation via a NOS-dependent pathway. This is not unex-
pected because activation of AMPK stimulates eNOS and 
therefore NO production in human aortic cells [33]. This 
indicates that AICAR and insulin have similar down-
stream actions leading to NO production and micro-
vascular recruitment in skeletal muscle. Importantly, in 
the current study L-NAME was infused locally into the 
hindleg of the rat, therefore AICAR-mediated microvas-
cular actions are due to local muscle NOS and not sys-
temic or central actions.
In the current study AICAR enhanced insulin-medi-
ated increases in skeletal muscle glucose uptake which 
were found to be dependent upon the fiber type com-
position of the muscles. Type I (slow twitch oxidative) 
muscles showed a decrease in insulin-mediated glucose 
uptake while the type IIA (fast twitch oxidative) and IIB 
(fast twitch glycolytic) muscles showed a marked increase 
in insulin-mediated glucose uptake. The fiber type spe-
cific effects of AICAR have also been reported by others 
at higher doses than used in the current study. Bergeron 
et al. [26] reported AICAR (0.58 mM, in vivo) to directly 
stimulate 2-DG uptake, in the absence of insulin, in the 
lateral and medial gastrocnemius and the soleus muscle. 
Iglesias et  al. [34] reported that subcutaneous injection 
of 250 mg/kg AICAR to insulin resistant high fat fed rats 
1  day before conducting a hyperinsulinemic euglycemic 
clamp markedly improved insulin-stimulated glucose 
uptake (2-DG) in white but not red quadriceps muscles. 
Follow up studies by Iglesias et al. [35] also revealed that 
significant enhancement of insulin stimulated glucose 
uptake in white muscle also occurred in normal rats. Ai 
et al. [36] also reported that 0.5–4 mM AICAR stimulated 
2-DG uptake occurred in incubated epitrochlearis, less 
in flexor digitorum brevis and not at all in soleus mus-
cle. Of these muscles, the epitrochlearis is richest in type 
IIB, the soleus in type I and the flexor digitorum brevis in 
type IIA fibers [36]. Ai et al. [36] also reported AMPKα1 
expression to be highest in the epitrochlearis and low-
est in the soleus; flexor digitorum brevis muscles had the 
lowest expression of AMPKα2. In contrast, Putman et al. 
[37] demonstrated that the α1 and α2 isoforms of AMPK 
are consistently expressed in a fiber type specific manner. 
They showed that both the α1 and α2 protein levels were 
greatest in the slow-twitch oxidative soleus, slightly less 
in the mixed fast-twitch red gastrocnemius, and lowest 
within the fast-twitch white gastrocnemius.
The in  vivo findings of this study provide evidence 
that AICAR increases insulin-mediated hindleg glucose 
uptake and 2-DG uptake. Despite this finding there was 
no increase in whole body glucose infusion rate (GIR). 
The GIR during the insulin + AICAR infusion was signif-
icantly reduced, such that by the end of the experiment 
the rate was approximately 30% less than during infu-
sion of insulin alone. This implies that AICAR inhibits 
the ability of insulin to suppress hepatic glucose output 
(HGO). A number of studies have provided in vivo evi-
dence for AICAR inhibiting insulin induced suppression 
of HGO. A study by Peneck et  al. [38] using conscious 
dogs, showed that intra-portal AICAR infusion of 1 mg/
min/kg abolished net hepatic glucose uptake and infu-
sion of 2  mg/min/kg stimulated net HGO. In another 
in vivo study by Camacho et al. [39] 1 mg/min/kg AICAR 
was infused into dogs for 90 min during a 2 mU/min/kg 
hyperinsulinemic insulin clamp. AICAR caused a stimu-
lation of both HGO and hepatic glycogenolysis even 
in the presence of physiological insulin. Another simi-
lar study by Camacho et al. [40] revealed that AICAR is 
effective in countering the suppressive effect of pharma-
cological insulin on net HGO which occurred even when 
AICAR-stimulated Acetyl CoA Carboxylase (ACC) phos-
phorylation was completely blocked by insulin. These 
findings indicate that, when activated, AMPK increases 
the availability of blood glucose to skeletal muscle by 
countering insulin induced inhibition of hepatic glu-
cose production. Thus AICAR induced HGO provides 
a reasonable explanation for the observed decrease in 
GIR during AICAR +  insulin treatment in this study in 
the presence of a net increase in skeletal muscle glucose 
uptake.
An additional set of experiments were performed 
with animals fasted for 40  h in which liver glycogen 
was depleted. In these animals a significantly increased 
a b
Figure 9 Effect of L-NAME on MvV during baseline (white), AICAR 
(hatched), and AICAR + contraction (cross hatched). Data are 
mean ± SE (Protocol C). Asterisk Significantly different (p < 0.05) from 
basal values; hash contraction treated significantly different from 
untreated; 2-way repeated-measures ANOVA.
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GIR was required to maintain euglycemia during the 
AICAR  +  insulin treatment compared with the cor-
responding overnight fasted treatment, while muscle 
glucose uptake (R’g), was unchanged (Figure  4) by the 
prolonged fasting period. This finding confirms that in 
overnight fasted animals AICAR inhibited insulin’s sup-
pression of HGO.
This study demonstrated that AICAR treatment had 
two potential detrimental actions in vivo. Firstly, AICAR 
treatment increased lactate production in resting mus-
cle. This finding is in agreement with other reports which 
have also observed an increase in lactate concentration 
with AICAR treatment in vitro [41, 42] and in vivo [26, 
39, 43]. Merrill et al. [42] using the perfused rat hindlimb, 
demonstrated that AICAR treatment (2  mM) increased 
lactate production by approximately twofold over 45 min 
compared with the control group. Bergeron et  al., [26] 
using conscious rats, also reported a marked increase 
in plasma lactate to about 13  mM at 90  min when the 
plasma levels of AICAR had reached 2.5  mM. Cama-
cho et  al. [39] also reported that AICAR significantly 
increased net hepatic lactate output in the presence of 
hypoglycemia. The increased blood lactate concentra-
tion in AICAR treated animals was also noted by Winder 
[44]. They suggested that AICAR increased intra-muscu-
lar glucose concentration, and the glucose was shunted 
towards lactate production rather than being oxidised. 
A number of studies have also demonstrated that AMPK 
phosphorylates phosphofructokinase and thereby stimu-
lates glycolysis [45–47] and this action is likely to account 
for the observed increase in net hepatic lactate produc-
tion. In addition, AICAR treatment has been reported to 
suppress heart rate, which is most likely due to actions 
via adenosine receptors in the heart [25, 48]. Although 
AICAR may have detrimental actions in vivo, the current 
project does highlight that other agents that operate via 
AMPK (e.g. vaspin [49] or CNX-012-570 [50]) are impor-
tant to follow-up as potential new drug targets for insulin 
resistance and type 2 diabetes.
The genetically obese Zucker, and lipid infused rats, 
both display impaired insulin-mediated glucose transport 
in skeletal muscle and insulin-mediated MvP is absent 
[14, 51]. In contrast, contraction-mediated glucose uptake 
by muscles in both of these insulin resistant rats appears 
to be essentially normal as does the increase in MvP 
in response to exercise [52, 53]. This suggests that the 
defects particular to insulin signaling may explain periph-
eral insulin resistance. Bergeron et  al. [28] have demon-
strated that acute infusion of AICAR in the Zucker rat 
increases glucose transport during a physiological insu-
lin clamp. The mechanism for enhanced insulin sensitiv-
ity in the Bergeron study may be partly due to increased 
MvP allowing greater access of insulin and glucose to the 
myocyte. However, in contrast, Lee-Young demonstrated 
that AICAR infusion into lipid infused mice did not over-
come the insulin resistance [54]. It is yet to be determined 
whether AICAR enhances insulin mediated MvP and thus 
glucose uptake in models of insulin resistance, such as the 
rat models described above.
Conclusions
Low dose AICAR stimulates MvP in skeletal muscle 
in vivo at a dose which does not stimulate glucose uptake 
by itself, and enhances insulin stimulated glucose uptake 
and MvP. The increase in MvP caused by AICAR is likely 
to enhance hormone and nutrient delivery to the mus-
cle myocytes which in turn increases glucose uptake in 
skeletal muscle when insulin is present. The AICAR 
enhanced insulin-stimulated glucose uptake occurred 
predominantly in the white fiber type muscles. AICAR 
inhibited insulin’s ability to increase whole body glucose 
uptake which is likely to be due to inhibition of insulin’s 
suppression of hepatic glucose output. The stimulation 
of lactate accumulation and the suppression of heart rate 
detract from the potential use of AICAR for the treat-
ment of insulin resistance.
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